Diagnose Algorithmus der pulmonalen Hypertonie und Screening-Verfahren

Khodr Tello; Manuel J. Richter; Nils Kremer; Henning Gall; Benjamin Egenlauf; Stephan Sorichter; Melanie Heberling; Philipp Douschan; Alfred Hager; Athiththan Yogeswaran; Jürgen Behr; Panagiota Xanthouli; Matthias Held

doi:10.1055/a-2145-4678

Pneumologie, Table of Contents

Pneumologie 2023; 77(11): 871-889
DOI: 10.1055/a-2145-4678

Übersicht

Diagnose Algorithmus der pulmonalen Hypertonie und Screening-Verfahren

Diagnostic Algorithm and Screening of Pulmonary Hypertension

Khodr Tello

¹Medizinische Klinik II, Justus-Liebig-Universität Gießen, Universitäten Gießen und Marburg Lung Center (UGMLC), Mitglied des Deutschen Zentrums für Lungenforschung (DZL), Deutschland

,

Manuel J. Richter

¹Medizinische Klinik II, Justus-Liebig-Universität Gießen, Universitäten Gießen und Marburg Lung Center (UGMLC), Mitglied des Deutschen Zentrums für Lungenforschung (DZL), Deutschland

,

Nils Kremer

¹Medizinische Klinik II, Justus-Liebig-Universität Gießen, Universitäten Gießen und Marburg Lung Center (UGMLC), Mitglied des Deutschen Zentrums für Lungenforschung (DZL), Deutschland

,

Henning Gall

¹Medizinische Klinik II, Justus-Liebig-Universität Gießen, Universitäten Gießen und Marburg Lung Center (UGMLC), Mitglied des Deutschen Zentrums für Lungenforschung (DZL), Deutschland

,

Benjamin Egenlauf

²Zentrum für pulmonale Hypertonie, Thoraxklinik Heidelberg gGmbH am Universitätsklinikum Heidelberg, Heidelberg, Deutschland, Mitglied des Deutschen Zentrums für Lungenforschung (DZL)

,

Stephan Sorichter

³Klinik für Pneumologie und Beatmungsmedizin, St.-Josefskrankenhaus, Freiburg im Breisgau, Deutschland

,

Melanie Heberling

⁴Universitätsklinikum Dresden, Med. Klinik I, Pneumologie, Dresden, Deutschland

,

Philipp Douschan

⁵Abteilung für Pulmonologie, Universitätsklinik für Innere Medizin, Graz, Österreich; Ludwig Boltzmann Institut für Lungengefäßforschung, Graz, Österreich

,

Alfred Hager

⁶Department of Paediatric Cardiology and Congenital Heart Defects, Deutsches Herzzentrum München, München, Deutschland

,

Athiththan Yogeswaran

¹Medizinische Klinik II, Justus-Liebig-Universität Gießen, Universitäten Gießen und Marburg Lung Center (UGMLC), Mitglied des Deutschen Zentrums für Lungenforschung (DZL), Deutschland

,

Jürgen Behr

⁷LMU Klinikum München, Medizinische Klinik und Poliklinik V, München, Deutschland. Comprehensive Pneumology Center (CPC-M), Mitglied des Deutschen Zentrums für Lungenforschung (DZL)

,

Panagiota Xanthouli

²Zentrum für pulmonale Hypertonie, Thoraxklinik Heidelberg gGmbH am Universitätsklinikum Heidelberg, Heidelberg, Deutschland, Mitglied des Deutschen Zentrums für Lungenforschung (DZL)

,

Matthias Held

⁸Klinikum Würzburg Mitte, Medizinische Klinik Schwerpunkt Pneumologie & Beatmungsmedizin, Würzburg, Deutschland

› Author Affiliations

Abstract

Zusammenfassung

Die neuen Leitlinien zur Diagnostik und Therapie der pulmonalen Hypertonie umfassen einen neuen diagnostischen Algorithmus und geben dezidierte Empfehlungen zu den erforderlichen Diagnostiken inklusive Screening-Verfahren ab. Diese Empfehlungen werden unter der Schirmherrschaft des PH-DACH von nationalen Experten kommentiert. Diese Kommentare bieten eine zusätzliche Entscheidungshilfe und Hintergrundinformationen und geben eine weitere Orientierung bei der komplexen Diagnostik der pulmonalen Hypertonie.

Abstract

The new guidelines for the diagnosis and treatment of pulmonary hypertension include a new diagnostic algorithm and provide specific recommendations for the required diagnostic procedures, including screening methods. These recommendations are commented on by national experts under the auspices of the DACH. These comments provide additional decision support and background information, serving as a further guide for the complex diagnosis of pulmonary hypertension.

Schlüsselwörter

pulmonale Hypertonie - Leitlinien - Diagnose - Screening

Keywords

pulmonary hypertension - guidelines - diagnose - screening

Full Text

References

Literatur
1 Didden EM. et al. Time to diagnosis of pulmonary hypertension and diagnostic burden: A retrospective analysis of nationwide US healthcare data. Pulm Circ 2023; 13: e12188
2 Nikkho SM. et al. Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative-Group 3 pulmonary hypertension. Pulm Circ 2022; 12: e12127
3 Humbert M. et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2023; 61.
4 Rich S. et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987; 107: 216-223
5 Bonderman D. et al. A noninvasive algorithm to exclude pre-capillary pulmonary hypertension. Eur Respir J 2011; 37: 1096-1103
6 Klok FA. et al. A simple non-invasive diagnostic algorithm for ruling out chronic thromboembolic pulmonary hypertension in patients after acute pulmonary embolism. Thromb Res 2011; 128: 21-26
7 Hendriks PM. et al. Role of the electrocardiogram in the risk stratification of pulmonary hypertension. Heart 2023; 109: 208-215
8 Hoeper MM. et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 2013; 62 (Suppl. 25) D42-D50
9 Galie N. et al. 2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. Rev Esp Cardiol (Engl Ed) 2016; 69: 177
10 Ascha M, Renapurkar RD, Tonelli AR. A review of imaging modalities in pulmonary hypertension. Ann Thorac Med 2017; 12: 61-73
11 Meyer FJ. et al. Peripheral airway obstruction in primary pulmonary hypertension. Thorax 2002; 57: 473-476
12 Sun XG. et al. Pulmonary function in primary pulmonary hypertension. J Am Coll Cardiol 2003; 41: 1028-1035
13 Hoeper MM. et al. Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis. Lancet Respir Med 2022; 10: 937-948
14 Trip P. et al. Diffusion capacity and BMPR2 mutations in pulmonary arterial hypertension. Eur Respir J 2014; 43: 1195-1198
15 Hoeper MM. et al. Diffusion Capacity and Mortality in Patients With Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction. JACC Heart Fail 2016; 4: 441-449
16 Olson TP, Johnson BD, Borlaug BA. Impaired Pulmonary Diffusion in Heart Failure With Preserved Ejection Fraction. JACC Heart Fail 2016; 4: 490-498
17 Olsson KM. et al. More on idiopathic pulmonary arterial hypertension with a low diffusing capacity. Eur Respir J 2017; 50: 1700354
18 Melot C, Naeije R. Pulmonary vascular diseases. Compr Physiol 2011; 1: 593-619
19 Jilwan FN. et al. High occurrence of hypoxemic sleep respiratory disorders in precapillary pulmonary hypertension and mechanisms. Chest 2013; 143: 47-55
20 Rudski LG. et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 2010; 23: 685-713
21 Lang RM. et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2015; 16: 233-270
22 Galderisi M. et al. Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantification, diastolic function, and heart valve disease recommendations: an expert consensus document of the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2017; 18: 1301-1310
23 Arcasoy SM. et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 2003; 167: 735-740
24 Fisher MR. et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med 2009; 179: 615-621
25 Farber HW. et al. REVEAL Registry: correlation of right heart catheterization and echocardiography in patients with pulmonary arterial hypertension. Congest Heart Fail 2011; 17: 56-64
26 D'Alto M. et al. Accuracy and precision of echocardiography versus right heart catheterization for the assessment of pulmonary hypertension. Int J Cardiol 2013; 168: 4058-4062
27 Huston JH. et al. Association of Mild Echocardiographic Pulmonary Hypertension With Mortality and Right Ventricular Function. JAMA Cardiol 2019; 4: 1112-1121
28 Gall H. et al. Validity of echocardiographic tricuspid regurgitation gradient to screen for new definition of pulmonary hypertension. EClinicalMedicine 2021; 34: 100822
29 Jankowich M, Maron BA, Choudhary G. Mildly elevated pulmonary artery systolic pressure on echocardiography: bridging the gap in current guidelines. Lancet Respir Med 2021; 9: 1185-1191
30 Vahanian A. et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur J Cardiothorac Surg 2021; 60: 727-800
31 Parent F. et al. A hemodynamic study of pulmonary hypertension in sickle cell disease. N Engl J Med 2011; 365: 44-53
32 Fonseca GH. et al. Pulmonary hypertension diagnosed by right heart catheterisation in sickle cell disease. Eur Respir J 2012; 39: 112-118
33 Grunig E. et al. Reference values for and determinants of right atrial area in healthy adults by 2-dimensional echocardiography. Circ Cardiovasc Imaging 2013; 6: 117-124
34 Guazzi M. et al. RV Contractile Function and its Coupling to Pulmonary Circulation in Heart Failure With Preserved Ejection Fraction: Stratification of Clinical Phenotypes and Outcomes. JACC Cardiovasc Imaging 2017; 10: 1211-1221
35 Tello K. et al. Relevance of the TAPSE/PASP ratio in pulmonary arterial hypertension. Int J Cardiol 2018; 266: 229-235
36 Tello K. et al. Validation of the Tricuspid Annular Plane Systolic Excursion/Systolic Pulmonary Artery Pressure Ratio for the Assessment of Right Ventricular-Arterial Coupling in Severe Pulmonary Hypertension. Circ Cardiovasc Imaging 2019; 12: e009047
37 Arkles JS. et al. Shape of the right ventricular Doppler envelope predicts hemodynamics and right heart function in pulmonary hypertension. Am J Respir Crit Care Med 2011; 183: 268-276
38 Takahama H. et al. Unraveling the RV Ejection Doppler Envelope: Insight Into Pulmonary Artery Hemodynamics and Disease Severity. JACC Cardiovasc Imaging 2017; 10: 1268-1277
39 Baumgartner H. et al. 2020 ESC Guidelines for the management of adult congenital heart disease. Eur Heart J 2021; 42: 563-645
40 Pieske B. et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J 2019; 40: 3297-3317
41 Lang RM. et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the american society of echocardiography and the European association of cardiovascular imaging. J Am Soc Echocardiogr 2015; 28: 1-39 e14
42 Badano LP. et al. How to do right ventricular strain. Eur Heart J Cardiovasc Imaging 2020. Eur Heart J Cardiovasc Imaging 2020; 21: 825-827
43 Xanthouli P. et al. Prognostic meaning of right ventricular function and output reserve in patients with systemic sclerosis. Arthritis Res Ther 2022; 24: 173
44 Richter MJ. et al. Imaging the right atrium in pulmonary hypertension: A systematic review and meta-analysis. J Heart Lung Transplant 2023; 42: 433-446
45 Kim NH. et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J 2019; 53: 1801915
46 Konstantinides SV. et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2020; 41: 543-603
47 Tunariu N. et al. Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. J Nucl Med 2007; 48: 680-684
48 He J. et al. Diagnosis of chronic thromboembolic pulmonary hypertension: comparison of ventilation/perfusion scanning and multidetector computed tomography pulmonary angiography with pulmonary angiography. Nucl Med Commun 2012; 33: 459-463
49 Seferian A. et al. Ventilation/perfusion lung scan in pulmonary veno-occlusive disease. Eur Respir J 2012; 40: 75-83
50 Giordano J. et al. Lung perfusion characteristics in pulmonary arterial hypertension (PAH) and peripheral forms of chronic thromboembolic pulmonary hypertension (pCTEPH): Dual-energy CT experience in 31 patients. Eur Radiol 2017; 27: 1631-1639
51 Remy-Jardin M. et al. Imaging of Pulmonary Hypertension in Adults: A Position Paper from the Fleischner Society. Radiology 2021; 298: 531-549
52 Lasch F. et al. Comparison of MRI and VQ-SPECT as a Screening Test for Patients With Suspected CTEPH: CHANGE-MRI Study Design and Rationale. Front Cardiovasc Med 2020; 7: 51
53 Dong C. et al. Diagnostic accuracy of computed tomography for chronic thromboembolic pulmonary hypertension: a systematic review and meta-analysis. PLoS One 2015; 10: e0126985
54 Rajaram S. et al. Diagnostic accuracy of contrast-enhanced MR angiography and unenhanced proton MR imaging compared with CT pulmonary angiography in chronic thromboembolic pulmonary hypertension. Eur Radiol 2012; 22: 310-317
55 Tamura M. et al. Diagnostic accuracy of lung subtraction iodine mapping CT for the evaluation of pulmonary perfusion in patients with chronic thromboembolic pulmonary hypertension: Correlation with perfusion SPECT/CT. Int J Cardiol 2017; 243: 538-543
56 Masy M. et al. Dual-energy CT (DECT) lung perfusion in pulmonary hypertension: concordance rate with V/Q scintigraphy in diagnosing chronic thromboembolic pulmonary hypertension (CTEPH). Eur Radiol 2018; 28: 5100-5110
57 Guerin L. et al. Prevalence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. Prevalence of CTEPH after pulmonary embolism. Thromb Haemost 2014; 112: 598-605
58 Ende-Verhaar YM. et al. Usefulness of standard computed tomography pulmonary angiography performed for acute pulmonary embolism for identification of chronic thromboembolic pulmonary hypertension: results of the InShape III study. J Heart Lung Transplant 2019; 38: 731-738
59 Schussler A. et al. Evaluation of Diagnostic Accuracy and Radiation Exposure of Dual-Energy Computed Tomography (DECT) in the Course of Chronic Thromboembolic Pulmonary Hypertension (CTEPH). Rofo 2021; 193: 1318-1326
60 Alabed S. et al. Cardiac-MRI Predicts Clinical Worsening and Mortality in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. JACC Cardiovasc Imaging 2021; 14: 931-942
61 Connors JM. Thrombophilia Testing and Venous Thrombosis. N Engl J Med 2017; 377: 2298
62 Sun XG. et al. Exercise pathophysiology in patients with primary pulmonary hypertension. Circulation 2001; 104: 429-435
63 Boerrigter BG. et al. Ventilatory and cardiocirculatory exercise profiles in COPD: the role of pulmonary hypertension. Chest 2012; 142: 1166-1174
64 Caravita S. et al. Pulmonary hypertension and ventilation during exercise: Role of the pre-capillary component. J Heart Lung Transplant 2017; 36: 754-762
65 Dumitrescu D. et al. Cardiopulmonary exercise testing for detecting pulmonary arterial hypertension in systemic sclerosis. Heart 2017; 103: 774-782
66 Weatherald J. et al. Ventilatory efficiency in pulmonary vascular diseases. Eur Respir Rev 2021; 30: 200214
67 Held M. et al. Functional Characterization of Patients with Chronic Thromboembolic Disease. Respiration 2016; 91: 503-509
68 Meyer FJ. et al. [Exercise Testing in Respiratory Medicine – DGP Recommendations]. Pneumologie 2018; 72: 687-731
69 Mehra MR. et al. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update. J Heart Lung Transplant 2016; 35: 1-23
70 Hoeper MM. et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol 2006; 48: 2546-2552
71 Kovacs G. et al. Zero reference level for right heart catheterisation. Eur Respir J 2013; 42: 1586-1594
72 Viray MC. et al. Role of Pulmonary Artery Wedge Pressure Saturation During Right Heart Catheterization: A Prospective Study. Circ Heart Fail 2020; 13: e007981
73 Callan P, Clark AL. Right heart catheterisation: indications and interpretation. Heart 2016; 102: 147-157
74 Maron BA. et al. Cardiopulmonary Hemodynamics in Pulmonary Hypertension and Heart Failure: JACC Review Topic of the Week. J Am Coll Cardiol 2020; 76: 2671-2681
75 Bootsma IT. et al. The contemporary pulmonary artery catheter. Part 1: placement and waveform analysis. J Clin Monit Comput 2022; 36: 5-15
76 Yogeswaran A. et al. Evaluation of pulmonary hypertension by right heart catheterisation: does timing matter?. Eur Respir J 2020; 56
77 Sitbon O. et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111: 3105-3111
78 Hoeper MM. et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. J Am Coll Cardiol 2000; 35: 176-182
79 Opitz CF. et al. Assessment of the vasodilator response in primary pulmonary hypertension. Comparing prostacyclin and iloprost administered by either infusion or inhalation. Eur Heart J 2003; 24: 356-365
80 Jing ZC. et al. Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension. Eur Respir J 2009; 33: 1354-1360
81 Chandrasekara S. et al. Acute Vasoreactivity Testing and Outcomes in Pulmonary Arterial Hypertension: A Call for Increased Testing. Heart Lung Circ 2023; 32: 156-165
82 Kovacs G. et al. An official European Respiratory Society statement: pulmonary haemodynamics during exercise. Eur Respir J 2017; 50: 1700578
83 Guth S. et al. Exercise right heart catheterisation before and after pulmonary endarterectomy in patients with chronic thromboembolic disease. Eur Respir J 2018; 52: 1800458
84 Claeys M. et al. Impaired Cardiac Reserve and Abnormal Vascular Load Limit Exercise Capacity in Chronic Thromboembolic Disease. JACC Cardiovasc Imaging 2019; 12: 1444-1456
85 Zeder K. et al. Exercise Pulmonary Resistances Predict Long-Term Survival in Systemic Sclerosis. Chest 2021; 159: 781-790
86 Naeije R. et al. Exercise-induced pulmonary hypertension: physiological basis and methodological concerns. Am J Respir Crit Care Med 2013; 187: 576-583
87 Godinas L. et al. Diagnostic concordance of different criteria for exercise pulmonary hypertension in subjects with normal resting pulmonary artery pressure. Eur Respir J 2016; 48: 254-257
88 Boerrigter BG. et al. Measuring central pulmonary pressures during exercise in COPD: how to cope with respiratory effects. Eur Respir J 2014; 43: 1316-1325
89 Wolsk E. et al. The Influence of Age on Hemodynamic Parameters During Rest and Exercise in Healthy Individuals. JACC Heart Fail 2017; 5: 337-346
90 Andersen MJ. et al. Hemodynamic Response to Rapid Saline Infusion Compared with Exercise in Healthy Participants Aged 20-80 Years. J Card Fail 2019; 25: 902-910
91 Kovacs G. et al. The pulmonary haemodynamics during exercise – research network (PEX-NET) ERS Clinical Research Collaboration: investigating the prognostic relevance of exercise haemodynamics. Eur Respir J 2019; 53: 1900458
92 Gaine SP, Rubin LJ. Primary pulmonary hypertension. Lancet 1998; 352: 719-725
93 Barst RJ. et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43 (Suppl. 12) 40S-47S
94 Wiedenroth CB. et al. Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic disease. Pulm Circ 2018; 8: 2045893217753122
95 Douschan P. et al. Right ventricular-pulmonary arterial coupling and its relationship to exercise haemodynamics in a continuum of patients with pulmonary vascular disease due to chronic thromboembolism. Eur Respir J 2022; 60: 2200450
96 DʼAlto M. et al. Clinical Relevance of Fluid Challenge in Patients Evaluated for Pulmonary Hypertension. Chest 2017; 151: 119-126
97 Vachiery JL. et al. Pulmonary hypertension due to left heart disease. Eur Respir J 2019; 53: 1801897
98 van de Bovenkamp AA. et al. The Value of Passive Leg Raise During Right Heart Catheterization in Diagnosing Heart Failure With Preserved Ejection Fraction. Circ Heart Fail 2022; 15: e008935
99 D'Alto M. et al. A Fluid Challenge Test for the Diagnosis of Occult Heart Failure. Chest 2021; 159: 791-797
100 Kremer N. et al. Unmasking right ventricular-arterial uncoupling during fluid challenge in pulmonary hypertension. J Heart Lung Transplant 2022; 41: 345-355
101 Ewert R. et al. Exercise and fluid challenge during right heart catheterisation for evaluation of dyspnoea. Pulm Circ 2020; 10.
102 Morrell NW. et al. Genetics and genomics of pulmonary arterial hypertension. Eur Respir J 2019; 53: 1801899
103 Eichstaedt CA. et al. Genetic counselling and testing in pulmonary arterial hypertension: a consensus statement on behalf of the International Consortium for Genetic Studies in PAH. Eur Respir J 2023; 61: 2201471
104 Galie N. et al. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med 2015; 373: 834-844
105 Sitbon O. et al. Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respir Med 2019; 7: 594-604
106 Strange G. et al. Time from symptoms to definitive diagnosis of idiopathic pulmonary arterial hypertension: The delay study. Pulm Circ 2013; 3: 89-94
107 Armstrong I. et al. The patient experience of pulmonary hypertension: a large cross-sectional study of UK patients. BMC Pulm Med 2019; 19: 67
108 Ivarsson B, Johansson A, Kjellstrom B. The Odyssey from Symptom to Diagnosis of Pulmonary Hypertension from the Patients and Spouses Perspective. J Prim Care Community Health 2021; 12 21501327211029241
109 Kiely DG, Lawrie A, Humbert M. Screening strategies for pulmonary arterial hypertension. Eur Heart J Suppl 2019; 21: K9-K20
110 Coghlan JG. et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 2014; 73: 1340-1349
111 Weatherald J. et al. Screening for pulmonary arterial hypertension in systemic sclerosis. Eur Respir Rev 2019; 28: 190023
112 Montani D. et al. Screening for pulmonary arterial hypertension in adults carrying a BMPR2 mutation. Eur Respir J 2021; 58: 2004229
113 Krowka MJ. et al. International Liver Transplant Society Practice Guidelines: Diagnosis and Management of Hepatopulmonary Syndrome and Portopulmonary Hypertension. Transplantation 2016; 100: 1440-1452
114 Mancuso L. et al. Management of portopulmonary hypertension: new perspectives. World J Gastroenterol 2013; 19: 8252-8257
115 Sitbon O. et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med 2008; 177: 108-113
116 Aad G. et al. Measurement of top quark polarization in top-antitop events from proton-proton collisions at radicals=7 TeV using the ATLAS detector. Phys Rev Lett 2013; 111: 232002
117 Ende-Verhaar YM. et al. Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a contemporary view of the published literature. Eur Respir J 2017; 49: 1601792
118 Kiely DG. et al. Utilising artificial intelligence to determine patients at risk of a rare disease: idiopathic pulmonary arterial hypertension. Pulm Circ 2019; 9: 2045894019890549
119 Nagel C. et al. Stress Doppler echocardiography for early detection of systemic sclerosis-associated pulmonary arterial hypertension. Arthritis Res Ther 2015; 17: 165
120 Santaniello A. et al. Cardiopulmonary exercise testing in a combined screening approach to individuate pulmonary arterial hypertension in systemic sclerosis. Rheumatology (Oxford) 2020; 59: 1581-1586
121 Vandecasteele E. et al. Screening for pulmonary arterial hypertension in an unselected prospective systemic sclerosis cohort. Eur Respir J 2017; 49: 1602275
122 Coghlan JG. et al. Incidence of pulmonary hypertension and determining factors in patients with systemic sclerosis. Eur Respir J 2018; 51: 1701197
123 Semalulu T. et al. An evidence-based strategy to screen for pulmonary arterial hypertension in systemic sclerosis. Semin Arthritis Rheum 2020; 50: 1421-1427
124 Hachulla E. et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005; 52: 3792-3800
125 Humbert M. et al. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum 2011; 63: 3522-3530
126 Hao Y. et al. A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis. Arthritis Res Ther 2015; 17: 7
127 Thakkar V. et al. The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort study. Arthritis Res Ther 2013; 15: R193
128 Morrisroe K. et al. Epidemiology and disease characteristics of systemic sclerosis-related pulmonary arterial hypertension: results from a real-life screening programme. Arthritis Res Ther 2017; 19: 42
129 Morrisroe K. et al. Risk factors for development of pulmonary arterial hypertension in Australian systemic sclerosis patients: results from a large multicenter cohort study. BMC Pulm Med 2016; 16: 134
130 Smith V. et al. Nailfold Videocapillaroscopy in Systemic Sclerosis-related Pulmonary Arterial Hypertension: A Systematic Literature Review. J Rheumatol 2020; 47: 888-895
131 Larkin EK. et al. Longitudinal analysis casts doubt on the presence of genetic anticipation in heritable pulmonary arterial hypertension. Am J Respir Crit Care Med 2012; 186: 892-896
132 Colle IO. et al. Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study. Hepatology 2003; 37: 401-409
133 Kim WR. et al. Accuracy of Doppler echocardiography in the assessment of pulmonary hypertension in liver transplant candidates. Liver Transpl 2000; 6: 453-458
134 Raevens S. et al. Echocardiography for the detection of portopulmonary hypertension in liver transplant candidates: an analysis of cutoff values. Liver Transpl 2013; 19: 602-610
135 Pengo V. et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004; 350: 2257-2264
136 Golpe R. et al. Right ventricle dysfunction and pulmonary hypertension in hemodynamically stable pulmonary embolism. Respir Med 2010; 104: 1370-1376
137 Simonneau G, Hoeper MM. Evaluation of the incidence of rare diseases: difficulties and uncertainties, the example of chronic thromboembolic pulmonary hypertension. Eur Respir J 2017; 49: 1602522
138 Coquoz N. et al. Multicentre observational screening survey for the detection of CTEPH following pulmonary embolism. Eur Respir J 2018; 51: 1702505
139 Valerio L. et al. Chronic thromboembolic pulmonary hypertension and impairment after pulmonary embolism: the FOCUS study. Eur Heart J 2022; 43: 3387-3398
140 Wartski M, Collignon MA. Incomplete recovery of lung perfusion after 3 months in patients with acute pulmonary embolism treated with antithrombotic agents. THESEE Study Group. Tinzaparin ou Heparin Standard: Evaluation dans lʼEmbolie Pulmonaire Study. J Nucl Med 2000; 41: 1043-1048
141 Nijkeuter M. et al. Resolution of thromboemboli in patients with acute pulmonary embolism: a systematic review. Chest 2006; 129: 192-197
142 Sanchez O. et al. Perfusion defects after pulmonary embolism: risk factors and clinical significance. J Thromb Haemost 2010; 8: 1248-1255
143 Delcroix M. et al. ERS statement on chronic thromboembolic pulmonary hypertension. Eur Respir J 2021; 57: 2002828
144 Nilsson LT. et al. Dyspnea after pulmonary embolism: a nation-wide population-based case-control study. Pulm Circ 2021; 11 20458940211046831
145 Boon G. et al. Non-invasive early exclusion of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: the InShape II study. Thorax 2021; 76: 1002-1009
146 Held M. et al. Frequency and characterization of CTEPH and CTEPD according to the mPAP threshold > 20 mm Hg: Retrospective analysis from data of a prospective PE aftercare program. Respir Med 2023; 210: 107177
147 Young A. et al. Performance of the DETECT Algorithm for Pulmonary Hypertension Screening in a Systemic Sclerosis Cohort. Arthritis Rheumatol 2021; 73: 1731-1737
148 Coirier V. et al. Impact of Three Different Algorithms for the Screening of SSc-PAH and Comparison with the Decisions of a Multidisciplinary Team. Diagnostics (Basel) 2021; 11: 1738
149 Colalillo A. et al. The role of TAPSE/sPAP ratio in predicting pulmonary hypertension and mortality in the systemic sclerosis EUSTAR cohort. Autoimmun Rev 2023; 22: 103290
150 Kolaitis NA. et al. HIV-associated Pulmonary Arterial Hypertension: A Report from the Pulmonary Hypertension Association Registry. Am J Respir Crit Care Med 2022; 205: 1121-1124
151 Delcroix M, Kerr K, Fedullo P. Chronic Thromboembolic Pulmonary Hypertension. Epidemiology and Risk Factors. Ann Am Thorac Soc 2016; 13 (Suppl. 03) S201-S206
152 Klok FA. et al. External validation of a simple non-invasive algorithm to rule out chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. Thromb Res 2015; 135: 796-801
153 Farmakis IT. et al. Cardiopulmonary exercise testing in the follow-up after acute pulmonary embolism. Eur Respir J 2023.